What Is Buprenorphine?
Buprenorphine is a partial opioid agonist used for both pain treatment and opioid addiction. Its unique pharmacology offers potential advantages over traditional opioids, including a ceiling effect on respiratory depression and less euphoria. It's increasingly used for chronic pain management.1
How It Works2
- Partial mu-opioid receptor agonist
- Kappa receptor antagonist
- Has a "ceiling effect"
- High receptor binding affinity
- Long duration of action
Formulations for Pain
Transdermal Patch (Butrans)
- Weekly patch
- 5, 7.5, 10, 15, 20 mcg/hour
- For moderate to severe chronic pain
Buccal Film (Belbuca)
- Dissolves in cheek
- Twice daily dosing
- Various strengths
Sublingual/Buccal (Suboxone)
- Often combined with naloxone
- Primarily for opioid use disorder
- Sometimes used for pain
Potential Advantages3
- Lower risk of respiratory depression
- Less constipation than some opioids
- May have less abuse potential
- Stable blood levels (patch)
- May help patients on high-dose opioids transition
- Less immunosuppressive
Common Side Effects
- Nausea (especially starting)
- Constipation
- Headache
- Dizziness
- Drowsiness
- Application site reactions (patch)
Important Considerations
- Schedule III controlled substance
- Can precipitate withdrawal if started wrong
- Special prescribing rules may apply
- Drug interactions exist
- Not easily reversed with naloxone
Who Might Consider
- Chronic pain requiring opioids
- History of opioid misuse concerns
- Desire to transition from other opioids
- Poor response to other opioids
- Medical conditions making other opioids risky
Starting Treatment
- Requires careful titration
- May need opioid-free interval first
- Start low, go slow
- Provider experienced with buprenorphine helpful
References
- Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209-219.
- Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859-870.
- Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428-450.